Immuno-oncology drugs showing results in hard-to-treat cancers; Express Scripts responds to Anthem lawsuit; BI and Lilly plan outcomes trials for Jardiance
Five things for pharma marketers to know: Friday, April 15, 2016
Cancer MoonShot 2020 to study childhood cancers; IBM’s purchase of Truven provides data about 200 million patients; overdoses tied to benzodiazepines rise
Five things for pharma marketers to know: Monday, January 11, 2016
Britain says Bristol-Myers Squibb’s Opdivo is too expensive; Calpers reports 32% boost in specialty drug spending; NIH is funding fewer clinical trials
Five things for pharma marketers to know: Tuesday, November 24, 2015
Opdivo receives another indication; increasing generic prescriptions may boost patient adherence; hep.-C drugs should be prescribed during earlier stages of disease
Five things for pharma marketers to know: Thursday, October 1, 2015
The FDA approves Opdivo/Yervoy combination to treat melanoma; BioMarin acquires global rights to Kuvan; Allergan’s Juvederm receives marketing approval for lip augmentation